Guardant Health Named BTIG’s Top Healthcare Pick
BTIG has reaffirmed its Buy rating on Guardant Health and increased its price target from $190 to $195, describing the company as a "must‑own" leader in specialty diagnostics. The recommendation follows Guardant’s strong second‑quarter performance, where the firm posted revenue of $335 million, representing a 44% year‑on‑year increase, and recorded a 63% rise in core oncology test volume.
The company also raised its full‑year guidance, though specific revised figures were not disclosed. BTIG highlights several upcoming catalysts: potential CMS coverage for the Guardant Reveal MRD assay in breast cancer, immunotherapy, and chemotherapy monitoring; the planned launch of Reveal Ultra MRD in the second half of 2026; and the pursuit of ADLT status for the FDA‑cleared G360 Smart Liquid test, slated for launch in the first half of 2027 at a higher price point.
Guardant is portrayed as the dominant player in the liquid‑biopsy market, supported by a large prospective ECLIPSE study involving approximately 20,000 patients for early colorectal cancer detection. Its product portfolio includes the Guardant360 CDx therapy‑selection test, Guardant Reveal, Guardant360 Tissue, Guardant360 Response (monitoring), and GuardantOMNI for biopharma customers. BTIG expects the company to expand these offerings across multiple cancer types, clinical settings, and global markets.
Other sell‑side analysts, including Stifel and TD Cowen, have also raised their price targets on Guardant Health following the same earnings beat and guidance upgrade.